Belite Bio, Inc
NCM: BLTELive Quote
About Belite Bio, Inc
Healthcare
Biotechnology
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
📊 Fundamental Analysis
Belite Bio, Inc demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -16.9%, which indicates that capital utilization is currently under pressure.
At a current price of $172.76, BLTE currently trades near the top of its 52-week range (81%) (Range: $53.59 - $200.00).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$5.60B
Trailing P/E
--
Forward P/E
220.08
Beta (5Y)
-1.22
52W High
$200.00
52W Low
$53.59
Avg Volume
190K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App